Loxo Oncology Inc (NASDAQ:LOXO) CEO Joshua H. Bilenker sold 20,000 shares of the business’s stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $166.20, for a total transaction of $3,324,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Shares of NASDAQ:LOXO opened at $164.00 on Monday. The firm has a market capitalization of $5.02 billion, a P/E ratio of -30.89 and a beta of 2.25. Loxo Oncology Inc has a 1 year low of $71.45 and a 1 year high of $208.95.
Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.54) by $0.15. The firm had revenue of $42.60 million for the quarter, compared to analyst estimates of $32.36 million. During the same period in the prior year, the firm earned ($0.94) EPS. analysts anticipate that Loxo Oncology Inc will post -0.47 EPS for the current fiscal year.
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research cut shares of Loxo Oncology from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. Cann reiterated a “buy” rating and issued a $202.00 price objective on shares of Loxo Oncology in a report on Monday. Stifel Nicolaus upped their price objective on shares of Loxo Oncology from $190.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, June 4th. BidaskClub upgraded shares of Loxo Oncology from a “buy” rating to a “strong-buy” rating in a report on Saturday, July 7th. Finally, Citigroup upped their price objective on shares of Loxo Oncology to $235.00 and gave the stock a “buy” rating in a report on Monday, June 4th. Two analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. Loxo Oncology currently has an average rating of “Buy” and an average target price of $188.40.
Institutional investors have recently added to or reduced their stakes in the business. Quantbot Technologies LP lifted its position in Loxo Oncology by 770.1% during the 1st quarter. Quantbot Technologies LP now owns 931 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 824 shares during the last quarter. Fortaleza Asset Management Inc. acquired a new position in Loxo Oncology during the 2nd quarter worth $110,000. IFP Advisors Inc lifted its position in Loxo Oncology by 509.6% during the 1st quarter. IFP Advisors Inc now owns 1,012 shares of the biopharmaceutical company’s stock worth $117,000 after acquiring an additional 846 shares during the last quarter. First Mercantile Trust Co. acquired a new position in Loxo Oncology during the 2nd quarter worth $122,000. Finally, Douglass Winthrop Advisors LLC acquired a new position in Loxo Oncology during the 2nd quarter worth $204,000. 97.46% of the stock is owned by hedge funds and other institutional investors.
About Loxo Oncology
Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.
Featured Article: What are Closed-End Mutual Funds?
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.